← Eichor
Study identifier: NCT07010705 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Condition: Huntington Disease · Healthy  ·  Sponsor: University of Rochester

PhaseN/A
Planned participants100
Who can joinAll sexes, 25 Years to 65 Years
Healthy volunteersYes

About this study

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.

This description comes directly from the study's public registry record.

Talk to the study team

Sugitha Maheswaran, BS  ·  5857040344  ·  Sugi_maheswaran@urmc.rochester.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Rochester Medical CenterRochester, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07010705